In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL). The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...
Read More
In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...
Read More
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read More
In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...
Read More
In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL). This study concluded that both treatments are safe and effective as a...
Read More
In a nutshell This study aimed to compare outcomes of salvage chemotherapy for patients with relapsed or refractory acute myeloid leukemia. This study concluded that the CLAG-M regimen (cladribine, cytarabine, filgrastim, and mitoxantrone) followed by transplant is a suitable salvage treatment for these patients. Some...
Read More
In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients. Some background Bruton...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia and small lymphocytic lymphoma. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients. Some background Bruton tyrosine...
Read MoreIn a nutshell This study aimed to investigate the outcome of early switching from imatinib to dasatinib of patients with chronic-phase chronic myeloid leukemia with weak responses to imatinib treatment. The study concluded that this switch may offer clinical benefit in certain patients. Some background Imatinib...
Read MoreIn a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...
Read MoreIn a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment. This study concluded that these patients have good outcomes with second-line TKI treatment. Some background Tyrosine kinase...
Read More
